InnovAge (INNV) Stock Forecast, Price Target & Predictions
INNV Stock Forecast
InnovAge stock forecast is as follows: an average price target of $6.80 (represents a 8.97% upside from INNV’s last price of $6.24) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
INNV Price Target
The average price target for InnovAge (INNV) is $6.80 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $5.00. This represents a potential 8.97% upside from INNV's last price of $6.24.
INNV Analyst Ratings
According to 3 Wall Street analysts, InnovAge's rating consensus is 'Hold'. The analyst rating breakdown for INNV stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 3 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
InnovAge Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Feb 08, 2023 | - | J.P. Morgan | $8.00 | $7.50 | 6.67% | 28.21% |
| Nov 23, 2022 | - | Goldman Sachs | $8.00 | $6.80 | 17.65% | 28.21% |
| Nov 16, 2022 | - | Citigroup | $8.00 | $7.25 | 10.34% | 28.21% |
| Sep 15, 2022 | - | Barclays | $5.00 | $4.94 | 1.21% | -19.87% |
| Apr 20, 2022 | - | Piper Sandler | $5.00 | $6.59 | -24.13% | -19.87% |
The latest InnovAge stock forecast, released on Feb 08, 2023 by J.P. Morgan company, set a price target of $8.00, which represents a 6.67% increase from the stock price at the time of the forecast ($7.50), and a 28.21% increase from INNV last price ($6.24).
InnovAge Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $6.24 | $6.24 | $6.24 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of InnovAge stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to InnovAge's last price of $6.24. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 23, 2022 | Goldman Sachs | Neutral | Neutral | Hold |
| Nov 16, 2022 | Citigroup | Neutral | Neutral | Hold |
| Dec 28, 2021 | Goldman Sachs | - | Neutral | Downgrade |
| Dec 27, 2021 | Barclays | - | Equal-Weight | Downgrade |
InnovAge's last stock rating was published by Goldman Sachs on Nov 23, 2022. The company gave INNV a "Neutral" rating, the same as its previous rate.
InnovAge Financial Forecast
InnovAge Revenue Forecast
| Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $188.90M | - | - | $172.54M | $167.46M | - | - | $177.36M | $175.35M | $173.07M | $171.62M | $156.31M |
| Avg Forecast | $237.53M | $242.69M | $237.47M | $232.03M | $213.90M | $218.90M | $209.58M | $204.02M | $191.43M | $188.16M | $183.92M | $177.89M | $175.77M | $174.14M | $169.75M | $171.61M | $173.77M | $170.11M | $174.18M | $170.89M | $164.02M | $157.21M |
| High Forecast | $237.53M | $242.69M | $237.47M | $232.03M | $213.90M | $218.90M | $209.58M | $204.02M | $192.42M | $188.16M | $186.44M | $180.01M | $175.77M | $174.14M | $169.75M | $171.61M | $173.77M | $171.67M | $175.79M | $172.47M | $165.53M | $158.66M |
| Low Forecast | $237.53M | $242.69M | $237.47M | $232.03M | $213.90M | $218.90M | $209.58M | $204.02M | $190.43M | $188.16M | $181.39M | $176.70M | $175.77M | $174.14M | $169.75M | $171.61M | $173.77M | $168.94M | $172.99M | $169.72M | $162.90M | $156.13M |
| # Analysts | 1 | 1 | - | - | - | - | 2 | 2 | 3 | 1 | 2 | 3 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.03% | - | - | 0.99% | 0.99% | - | - | 1.04% | 1.01% | 1.01% | 1.05% | 0.99% |
InnovAge's average Quarter revenue forecast for Mar 24 based on 1 analysts is $188.16M, with a low forecast of $188.16M, and a high forecast of $188.16M. INNV's average Quarter revenue forecast represents a -0.39% decrease compared to the company's last Quarter revenue of $188.90M (Dec 23).
InnovAge EBITDA Forecast
| Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | 2 | 2 | 3 | 1 | 2 | 3 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $50.03M | - | - | $-4.28M | $-9.57M | - | - | $-2.71M | $4.92M | $14.52M | $13.84M | $-6.59M |
| Avg Forecast | $8.89M | $9.08M | $8.89M | $8.69M | $8.01M | $8.19M | $7.85M | $7.64M | $7.17M | $7.04M | $6.88M | $6.66M | $6.58M | $6.52M | $6.35M | $6.42M | $6.50M | $-6.42M | $4.92M | $11.62M | $6.14M | $-7.25M |
| High Forecast | $8.89M | $9.08M | $8.89M | $8.69M | $8.01M | $8.19M | $7.85M | $7.64M | $7.20M | $7.04M | $6.98M | $6.74M | $6.58M | $6.52M | $6.35M | $6.42M | $6.50M | $-5.14M | $5.91M | $13.94M | $6.20M | $-5.80M |
| Low Forecast | $8.89M | $9.08M | $8.89M | $8.69M | $8.01M | $8.19M | $7.85M | $7.64M | $7.13M | $7.04M | $6.79M | $6.61M | $6.58M | $6.52M | $6.35M | $6.42M | $6.50M | $-7.70M | $3.94M | $9.29M | $6.10M | $-8.69M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 7.27% | - | - | -0.66% | -1.51% | - | - | 0.42% | 1.00% | 1.25% | 2.25% | 0.91% |
1 analysts predict INNV's average Quarter EBITDA for Mar 24 to be $7.04M, with a high of $7.04M and a low of $7.04M. This is -85.92% lower than InnovAge's previous annual EBITDA (Dec 23) of $50.03M.
InnovAge Net Income Forecast
| Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | 2 | 2 | 3 | 1 | 2 | 3 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-3.45M | - | - | $-7.31M | $-10.55M | - | - | $-3.16M | $1.11M | $7.69M | $6.47M | $-10.51M |
| Avg Forecast | - | - | - | - | $1.36M | $1.95M | $166.62K | $-754.83K | $-2.77M | $-4.75M | $-4.24M | $-5.01M | $-4.79M | $-6.44M | $-11.23M | $-4.02M | $-2.24M | $-7.62M | $1.11M | $6.15M | $8.83M | $-11.56M |
| High Forecast | - | - | - | - | $1.36M | $1.95M | $166.62K | $-754.83K | $-922.23K | $-4.75M | $-2.83M | $-2.50M | $-4.79M | $-6.44M | $-11.23M | $-4.02M | $-2.24M | $-6.09M | $1.33M | $7.38M | $8.93M | $-9.25M |
| Low Forecast | - | - | - | - | $1.36M | $1.95M | $166.62K | $-754.83K | $-3.69M | $-4.75M | $-4.24M | $-6.26M | $-4.79M | $-6.44M | $-11.23M | $-4.02M | $-2.24M | $-9.14M | $884.80K | $4.92M | $8.75M | $-13.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.81% | - | - | 1.14% | 0.94% | - | - | 0.41% | 1.00% | 1.25% | 0.73% | 0.91% |
InnovAge's average Quarter net income forecast for Mar 22 is $-7.62M, with a range of $-9.14M to $-6.09M. INNV's average Quarter net income forecast represents a -788.67% decrease compared to the company's last Quarter net income of $1.11M (Dec 21).
InnovAge SG&A Forecast
| Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | 2 | 2 | 3 | 1 | 2 | 3 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $31.11M | - | - | $32.96M | $32.59M | - | - | $30.83M | $35.16M | $27.38M | $34.33M | $24.19M |
| Avg Forecast | $42.50M | $43.42M | $42.49M | $41.52M | $38.27M | $39.17M | $37.50M | $36.50M | $34.25M | $33.67M | $32.91M | $31.83M | $31.45M | $31.16M | $30.37M | $30.71M | $31.09M | $83.23M | $35.16M | $21.90M | $29.35M | $26.61M |
| High Forecast | $42.50M | $43.42M | $42.49M | $41.52M | $38.27M | $39.17M | $37.50M | $36.50M | $34.43M | $33.67M | $33.36M | $32.21M | $31.45M | $31.16M | $30.37M | $30.71M | $31.09M | $99.88M | $42.19M | $26.28M | $29.62M | $31.93M |
| Low Forecast | $42.50M | $43.42M | $42.49M | $41.52M | $38.27M | $39.17M | $37.50M | $36.50M | $34.07M | $33.67M | $32.46M | $31.62M | $31.45M | $31.16M | $30.37M | $30.71M | $31.09M | $66.58M | $28.13M | $17.52M | $29.15M | $21.28M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.95% | - | - | 1.06% | 1.07% | - | - | 0.37% | 1.00% | 1.25% | 1.17% | 0.91% |
InnovAge's average Quarter SG&A projection for Mar 24 is $33.67M, based on 1 Wall Street analysts, with a range of $33.67M to $33.67M. The forecast indicates a 8.23% rise compared to INNV last annual SG&A of $31.11M (Dec 23).
InnovAge EPS Forecast
| Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | 2 | 2 | 3 | 1 | 2 | 3 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.03 | - | - | $-0.05 | $-0.08 | - | - | $-0.02 | $0.01 | $0.06 | $0.05 | $-0.09 |
| Avg Forecast | - | - | - | - | $0.01 | $0.01 | - | $-0.01 | $-0.02 | $-0.03 | $-0.03 | $-0.04 | $-0.04 | $-0.05 | $-0.08 | $-0.03 | $-0.02 | $-0.00 | $0.05 | $0.05 | $0.06 | $-0.10 |
| High Forecast | - | - | - | - | $0.01 | $0.01 | - | $-0.01 | $-0.01 | $-0.03 | $-0.02 | $-0.02 | $-0.04 | $-0.05 | $-0.08 | $-0.03 | $-0.02 | $-0.00 | $0.05 | $0.05 | $0.07 | $-0.10 |
| Low Forecast | - | - | - | - | $0.01 | $0.01 | - | $-0.01 | $-0.03 | $-0.03 | $-0.03 | $-0.05 | $-0.04 | $-0.05 | $-0.08 | $-0.03 | $-0.02 | $-0.00 | $0.05 | $0.05 | $0.06 | $-0.10 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.81% | - | - | 1.14% | 0.94% | - | - | 30.82% | 0.17% | 1.19% | 0.77% | 0.93% |
According to 0 Wall Street analysts, InnovAge's projected average Quarter EPS for Mar 22 is $-0.00, with a low estimate of $-0.00 and a high estimate of $-0.00. This represents a -109.22% decrease compared to INNV previous annual EPS of $0.01 (Dec 21).
InnovAge Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EHAB | Enhabit | $7.89 | $10.25 | 29.91% | Hold |
| MODV | ModivCare | $32.00 | $38.67 | 20.84% | Buy |
| SEM | Select Medical | $33.74 | $40.00 | 18.55% | Buy |
| INNV | InnovAge | $6.21 | $6.80 | 9.50% | Hold |
| EHC | Encompass Health | $91.66 | $93.17 | 1.65% | Buy |
| PNTG | Pennant Group | $31.84 | $30.67 | -3.67% | Buy |
| ENSG | Ensign Group | $149.05 | $114.25 | -23.35% | Buy |
INNV Forecast FAQ
Is InnovAge a good buy?
No, according to 3 Wall Street analysts, InnovAge (INNV) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of INNV's total ratings.
What is INNV's price target?
InnovAge (INNV) average price target is $6.8 with a range of $5 to $8, implying a 8.97% from its last price of $6.24. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will InnovAge stock go up soon?
According to Wall Street analysts' prediction for INNV stock, the company can go up by 8.97% (from the last price of $6.24 to the average price target of $6.8), up by 28.21% based on the highest stock price target, and down by -19.87% based on the lowest stock price target.
Can InnovAge stock reach $9?
INNV's average twelve months analyst stock price target of $6.8 does not support the claim that InnovAge can reach $9 in the near future.
Did the INNV's actual financial results beat the analysts' financial forecasts?
Based on InnovAge's last annual report (Jun 2021), the company's revenue was $637.8M, beating the average analysts forecast of $321.23M by 98.55%. Apple's EBITDA was $8.59M, missing the average prediction of $-1.106M by -876.83%. The company's net income was $-44.74M, beating the average estimation of $-2.732M by 1537.64%. Apple's SG&A was $154.57M, beating the average forecast of $55.95M by 176.24%. Lastly, the company's EPS was $-0.36, beating the average prediction of $-0.0321 by 1023.10%. In terms of the last quarterly report (Dec 2023), InnovAge's revenue was $188.9M, beating the average analysts' forecast of $183.92M by 2.71%. The company's EBITDA was $50.03M, beating the average prediction of $6.88M by 626.73%. InnovAge's net income was $-3.447M, missing the average estimation of $-4.241M by -18.72%. The company's SG&A was $31.11M, missing the average forecast of $32.91M by -5.47%. Lastly, the company's EPS was $-0.0254, missing the average prediction of $-0.0312 by -18.60%